Download PDF
Drug Res (Stuttg) 2014; 64(09): 454-461
DOI: 10.1055/s-0033-1361129
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

The Inhibition of Monoamine Oxidase by Phenformin and Pentamidine

M. Barkhuizen
1   Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South Africa
,
A. Petzer
2   Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University, Potchefstroom, South Africa
,
J. P. Petzer
1   Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South Africa
› Author Affiliations
Further Information

Publication History

received 01 October 2013

accepted 09 November 2013

Publication Date:
04 December 2013 (online)

Also available at
    Permissions and Reprints

Abstract

A computational study has suggested that phenformin, an oral hypoglycaemic drug, may bind to the active sites of the monoamine oxidase (MAO) A and B enzymes. The present study therefore investigates the MAO inhibitory properties of phenformin. Pentamidine, a structurally related diamidine compound, has previously been reported to be a MAO inhibitor and was included in this study as a reference compound. Using recombinant human MAO-A and MAO-B, this study finds that phenformin acts as a moderately potent MAO-A selective inhibitor with an IC50 value of 41 µM. Pentamidine, on the other hand, potently inhibits both MAO-A and MAO-B with IC50 values of 0.61 μM and 0.22 μM, respectively. An examination of the recoveries of the enzymatic activities after dilution and dialysis of the enzyme-inhibitor complexes shows that both compounds interact reversibly with the MAO enzymes. A kinetic analysis suggests that pentamidine acts as a competitive inhibitor with estimated Ki values of 0.41 μM and 0.22 μM for the inhibition of MAO-A and MAO-B, respectively. Phenformin also exhibited a competitive mode of MAO-A inhibition with an estimated Ki value of 65 µM. This study concludes that biguanide and amidine functional groups are most likely important structural features for the inhibition of the MAOs by phenformin and pentamidine, and compounds containing these and closely related functional groups should be considered as potential MAO inhibitors. Furthermore, the biguanide and amidine functional groups may act as useful moieties in the future design of MAO inhibitors.

Key words

biguanides - amidines - guanidine - phenformin - pentamidine - inhibition - monoamine oxidase
 

  • References

  • 1 Xian M, Li X, Tang X et al. N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors. Bioorg Med Chem Lett 2001; 11: 2377-2380
    CrossrefPubMedSearch in Google Scholar
  • 2 Berlinck RG. Natural guanidine derivatives. Nat Prod Rep 1996; 13: 377-409
    CrossrefPubMedSearch in Google Scholar
  • 3 Berlinck RG, Burtoloso AC, Kossuga MH. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2008; 25: 919-954
    CrossrefPubMedSearch in Google Scholar
  • 4 Malinow SH. Comparison of guanadrel and guanethidine efficacy and side effects. Clin Ther 1983; 5: 284-289
    PubMedSearch in Google Scholar
  • 5 Giroud C, Moreau M, Mattioli TA et al. Role of arginine guanidinium moiety in nitric-oxide synthase mechanism of oxygen activation. J Biol Chem 2010; 285: 7233-7245
    CrossrefPubMedSearch in Google Scholar
  • 6 Guthrie RM. Evolving therapeutic options for type 2 diabetes mellitus: an overview. Postgrad Med 2012; 124: 82-89
    CrossrefPubMedSearch in Google Scholar
  • 7 Fimognari FL, Pastorelli R, Incalzi RA. Phenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis). Diabetes Care 2006; 29: 950-951
    CrossrefPubMedSearch in Google Scholar
  • 8 Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33
    CrossrefPubMedSearch in Google Scholar
  • 9 Aziz Q, Thomas A, Khambra T et al. Phenformin has a direct inhibitory effect on the ATP-sensitive potassium channel. Eur J Pharmacol 2010; 634: 26-32
    CrossrefPubMedSearch in Google Scholar
  • 10 Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-341
    CrossrefPubMedSearch in Google Scholar
  • 11 Dilman VM, Berstein LM, Zabezhinski MA et al. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch Geschwulstforsch 1978; 48: 1-8
    PubMedSearch in Google Scholar
  • 12 Appleyard MV, Murray KE, Coates PJ et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer 2012; 106: 1117-1122
    CrossrefPubMedSearch in Google Scholar
  • 13 Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305
    CrossrefPubMedSearch in Google Scholar
  • 14 Wispelwey B, Pearson RD. Pentamidine: a review. Infect Control Hosp Epidemiol 1991; 12: 375-382
    CrossrefPubMedSearch in Google Scholar
  • 15 Blaschko H, Duthie R. The inhibition of amine oxidase by amidines. Biochem J 1945; 39: 347-350
    PubMedSearch in Google Scholar
  • 16 Davison AN. The irreversible inhibition of monoamine oxidase in vivo. Arch Biochem Biophys 1958; 77: 368-371
    CrossrefPubMedSearch in Google Scholar
  • 17 Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 2006; 147 (Suppl. 01) S287-S296
    PubMedSearch in Google Scholar
  • 18 Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004; 25: 215-221
    CrossrefPubMedSearch in Google Scholar
  • 19 Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295-309
    CrossrefPubMedSearch in Google Scholar
  • 20 Finberg JP, Wang J, Bankiewicz K et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl 1998; 52: 279-285
    PubMedSearch in Google Scholar
  • 21 Da Prada M, Zürcher G, Wüthrich I et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 1988; 26: 31-56
    PubMedSearch in Google Scholar
  • 22 Harfenist M, Heuser DJ, Joyner CT et al. Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups. J Med Chem 1996; 39: 1857-1863
    CrossrefPubMedSearch in Google Scholar
  • 23 Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007; 152: 946-951
    CrossrefPubMedSearch in Google Scholar
  • 24 Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol 2010; 24: 1433-1438
    CrossrefPubMedSearch in Google Scholar
  • 25 Soriato G, Focati MP, Brescello R et al. Pharmaceutical preparations of crystalline lazabemide. Patent 2008 WO 2008010794
    PubMedSearch in Google Scholar
  • 26 Petzer A, Harvey BH, Wegener G et al. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol 2012; 258: 403-409
    CrossrefPubMedSearch in Google Scholar
  • 27 Novaroli L, Reist M, Favre E et al. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem 2005; 13: 6212-6217
    CrossrefPubMedSearch in Google Scholar
  • 28 Strydom B, Bergh JJ, Petzer JP. The inhibition of monoamine oxidase by 8-(2-phenoxyethoxy)caffeine analogues. Arzneimittelforschung 2012; 62: 513-518
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Manley-King CI, Bergh JJ, Petzer JP. Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Bioorg Med Chem 2011; 19: 261-274
    CrossrefPubMedSearch in Google Scholar
  • 30 Petzer A, Pienaar A, Petzer JP. The Inhibition of Monoamine Oxidase by Esomeprazole. Arzneimittelforschung 2013; 63: 462-467
    PubMedSearch in Google Scholar
  • 31 Oates NS, Shah RR, Idle JR et al. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34: 827-834
    CrossrefPubMedSearch in Google Scholar
  • 32 Provost JC, Funck-Brentano C, Rovei V et al. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther 1992; 52: 384-393
    CrossrefPubMedSearch in Google Scholar
  • 33 Boulton AA. Phenylethylaminergic modulation of catecholaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 139-156
    CrossrefPubMedSearch in Google Scholar
  • 34 Lasbennes F, Sercombe R, Seylaz J. Monoamine oxidase activity in brain microvessels determined using natural and artificial substrates: relevance to the blood-brain barrier. J Cereb Blood Flow Metab 1983; 3: 521-528
    CrossrefPubMedSearch in Google Scholar
  • 35 Finberg JP, Lamensdorf I, Armoni T. Modification of dopamine release by selective inhibitors of MAO-B. Neurobiology (Bp) 2000; 8: 137-142
    PubMedSearch in Google Scholar
  • 36 Pae CU, Bodkin JA, Portland KB et al. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. J Clin Psychiatry 2012; 73: 661-668
    CrossrefPubMedSearch in Google Scholar
  • 37 Binda C, Newton-Vinson P, Hubálek F et al. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002; 9: 22-26
    CrossrefPubMedSearch in Google Scholar
  • 38 Binda C, Wang J, Pisani L et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007; 50: 5848-5852
    CrossrefPubMedSearch in Google Scholar
  • 39 Hubálek F, Binda C, Khalil A et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 2005; 280: 15761-15766
    CrossrefPubMedSearch in Google Scholar
  • 40 Son SY, Ma J, Kondou Y et al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008; 105: 5739-5744
    CrossrefPubMedSearch in Google Scholar